Analyst Price Targets — IRON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:34 pm | — | Wedbush | $88.00 | $60.28 | TheFly | Disc Medicine price target lowered to $88 from $110 at Wedbush |
| February 17, 2026 1:21 pm | Kristen Kluska | Cantor Fitzgerald | $125.00 | $60.24 | TheFly | Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald |
| February 17, 2026 1:14 pm | — | Morgan Stanley | $75.00 | $60.39 | TheFly | Disc Medicine price target lowered to $75 from $120 at Morgan Stanley |
| February 17, 2026 1:05 pm | — | Stifel Nicolaus | $110.00 | $61.43 | TheFly | Disc Medicine price target lowered to $110 from $125 at Stifel |
| February 17, 2026 12:56 pm | Evan Seigerman | BMO Capital | $100.00 | $61.48 | TheFly | Disc Medicine price target lowered to $100 from $120 at BMO Capital |
| January 8, 2026 12:40 pm | — | Morgan Stanley | $120.00 | $80.94 | TheFly | Disc Medicine price target raised to $120 from $115 at Morgan Stanley |
| December 8, 2025 1:20 pm | Martin Auster | Raymond James | $117.00 | $96.32 | StreetInsider | Disc Medicine (IRON) PT Raised to $117 at Raymond James |
| November 10, 2025 2:52 pm | — | Truist Financial | $114.00 | $82.77 | TheFly | Disc Medicine price target raised to $114 from $86 at Truist |
| October 17, 2025 1:04 pm | — | National Bank | $153.00 | $94.19 | TheFly | Disc Medicine price target raised to $153 from $132 at Cantor Fitzgerald |
| October 17, 2025 12:01 pm | — | Raymond James | $108.00 | $74.36 | TheFly | Disc Medicine price target raised to $108 from $89 at Raymond James |
Latest News for IRON
New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Disc Medicine securities you may…
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRON.
U.S. House Trading
No House trades found for IRON.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.